Leap Therapeutics, Inc. (LPTX) has a negative trailing P/E of -2.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -34.09%.
Criteria proven by this page:
Overall SharesGrow Score: 66/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.9 | -0.02 | -0.74 | 0.00 | - |
| 2017 | -1.9 | -0.10 | 5.14 | 0.00 | - |
| 2018 | -1.2 | 0.02 | 3.08 | 0.00 | - |
| 2019 | -7.3 | 0.67 | 4.42 | 2.61 | - |
| 2020 | -39.4 | 0.58 | 1.98 | 13.28 | - |
| 2021 | -6.9 | -3.53 | 2.58 | 185.38 | - |
| 2022 | -0.9 | -0.49 | 0.93 | 0.00 | - |
| 2023 | -1.0 | 0.06 | 1.41 | 0.00 | - |
| 2024 | -1.6 | 0.03 | 3.09 | 0.00 | - |
| 2025 | 15.9 | -0.15 | 0.50 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-27.29 | $0.00 | $-25.63M | - |
| 2017 | $-32.35 | $0.00 | $-29.73M | - |
| 2018 | $-16.05 | $0.00 | $-23.14M | - |
| 2019 | $-14.57 | $0.00 | $-32.9M | - |
| 2020 | $-4.64 | $1.5M | $-27.51M | -1834.3% |
| 2021 | $-4.73 | $1.5M | $-40.59M | -2705.8% |
| 2022 | $-4.82 | $0.00 | $-54.6M | - |
| 2023 | $-3.98 | $0.00 | $-81.41M | - |
| 2024 | $-1.81 | $0.00 | $-67.56M | - |
| 2025 | $0.07 | $0.00 | $4.82M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.53 | $-0.53 – $-0.53 | $6M | $6M – $6M | 1 |
| 2027 | $-0.55 | $-0.55 – $-0.55 | $9.88M | $9.88M – $9.88M | 1 |
| 2028 | $-0.63 | $-0.63 – $-0.63 | $8.2M | $8.2M – $8.2M | 1 |
| 2029 | $-0.23 | $-0.23 – $-0.23 | $39.43M | $39.43M – $39.43M | 1 |
